Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Thomas Holst‐Hansen's publication output changed over time?
ScholarIQpublication output · 2021–2025
Output grew0% over the shown period — from 1 works in 2021 to 1 in 2025.
1
2
3
3
1
20212022202320242025
What are the most-cited papers on Thomas Holst‐Hansen?
ScholarIQmost cited works
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip K. Knop, Vanita R. Aroda, Ruben D do Vale, Thomas Holst‐Hansen, Peter Nørkjær Laursen, Julio Rosenstock, Domenica Rubino, W. Timothy Garvey
The Lancet. 2023389 Citations
Spatiotemporal NF-κB dynamics encodes the position, amplitude, and duration of local immune inputs
Minjun Son, Tino Frank, Thomas Holst‐Hansen, Andrew G. Wang, Michael Junkin, Sara Saheb Kashaf, Ala Trusina, Savaş Tay
S2737427234. 202247 CitationsOPEN ACCESS
Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity
Lua Wilkinson, Thomas Holst‐Hansen, Peter Nørkjær Laursen, Anders R. Rinnov, Rachel L. Batterham, W. Timothy Garvey
Obesity. 202320 CitationsOPEN ACCESS
The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis
Xiao Wen Luah, Thomas Holst‐Hansen, Christopher Lübker
Diabetes Obesity and Metabolism. 202414 CitationsOPEN ACCESS
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial
Filip K. Knop, George Kunos, Dror Dicker, Jean‐Sébastien Paquette, Louis J. Aronne, Ofir Frenkel, Thomas Holst‐Hansen, Karine Lalonde, Jisoo Lee, Glenn Crater
The Lancet Diabetes & Endocrinology. 202510 CitationsOPEN ACCESS
Related on ScholarIQ
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Paper
Spatiotemporal NF-κB dynamics encodes the position, amplitude, and duration of local immune inputs
Paper
Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity
Paper
The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis
Paper
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial
Paper
2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity
Paper